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Comment on
Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, et al. Assessment of
symptomatic women for early diagnosis of ovarian cancer: results from the
prospective DOvE pilot project. Lancet Oncol 2012;13(3):285-91.
In their recent study, Gilbert et al1 were able to detect high grade serous ovarian
cancer (HGSC) by screening symptomatic women. While they were not able to
diagnose early stage disease, there was a suggestion of lower (not clearly defined)
tumour burden. This was accompanied by a trend to higher complete resection rates
in study women (73%) diagnosed with ovarian cancer (OC) compared to patients
(44%) diagnosed outside the study during the same period (standard care). The data
is encouraging and echoes our experience of large OC screening trials2 3 in the
general population. Complete resection with no gross residual disease has been
shown to be associated with superior survival outcomes in patients with advanced-
stage epithelial OC.4 We believe low volume Stage III disease may have contributed
to the significant difference in 5-year survival observed in our first OC screening
randomised controlled trial (RCT).2
We commend the team on the huge effort invested in performing this study but
would like to point out a key issue related to study design. The findings of a trend in
nine patients diagnosed with OC in their single arm prospective pilot study, however
encouraging, may to a large extent be due to a 'healthy volunteer effect' (HVE). The
DOvE cohort have all the hallmarks (younger, more educated, more English
speaking) of one which would be associated with a marked HVE. In the control (no
intervention) arm of our United Kingdom Collaborative Trial of Ovarian Cancer
Screening, the overall standardised mortality rate was 37.3% compared to the age
matched UK population. The HVE in cancer was more pronounced with regard to
mortality (standardised cancer specific mortality rate 55.9%) compared to incidence
(standardised cancer incidence rate 88.1%).5 This was also observed in the control
arm of the PLCO trial.6 In addition the inference is limited by inability to control for
preferential selection of patients to DoVE rather than standard care.
In a recent UK multicentre study, we have found that in two thirds of symptomatic
patients, it may be possible to bring the OC diagnosis forward by 3 months or more.7
While this is a significant proportion of patients, the window of opportunity for a
symptom based algorithm to impact on optimal resection is small. The resulting
improved survival may be a worthwhile end point even in the absence of a mortality
benefit in symptomatic women presenting to clinicians as opposed to asymptomatic
women. However it needs to be balanced by the risks to the women who do not have
OC and the resource implications of such a strategy.
The authors plan to expand the single arm study by setting up satellite clinics and
introducing widespread symptom awareness measures. Given the inherent issues of
this study design, we would strongly urge them to consider validating their
preliminary findings in a prospective multicentre RCT to ensure the trend observed is
not due solely to HVE and address the balance of risk versus benefits for the whole
cohort.
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